Viloxazine

Category: pharmacological

Aliases: Qelbree

Pharmacological Mechanism

Selective NET inhibition + 5-HT2C agonism + 5-HT2B antagonism. Non-stimulant ADHD treatment approved 2021 (originally marketed in Europe as antidepressant 1970s-2002). No abuse potential.

Half-Life (t½)

PO: 7h

Dosing Guidelines

• PO: Typical 267mg (Range: 100 - 600 mg)

Target Organ Systems

• nervous